United Kingdom· GB-APID-38221511000001107
Polivy 140mg powder for concentrate for solution for infusion vials
A polatuzumab vedotin product containing polatuzumab vedotin, registered in United Kingdom by Roche Products Ltd. The same ATC class is registered in 13 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Polatuzumab vedotin is registered in 13 of 19 countries.
Countries holding a registration under ATC L01FX14 (polatuzumab vedotin), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 8 of them publish a price we can compare per daily dose
Polatuzumab vedotin · ATC L01FX14
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of polatuzumab vedotin costs, country by country.
Normalised to the WHO defined daily dose (6 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Polatuzumab vedotin · price per daily dose (6 mg)
USD · FX 28 Sept 2026
- CH Switzerland$513.20
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Polatuzumab vedotin
- Manufacturer
- Roche Products Ltd
- Country
- United Kingdom (GB)
- ATC code
- L01FX14
- ATC class
- Polatuzumab vedotin
- Defined daily dose
- 6 mg, P
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 2
- gtin7613326024082
- gtin07613326024082
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
177 interactions on record for polatuzumab vedotin.
Graded by severity as the source publishes them — 37 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Polatuzumab vedotin · interactions on record
177 records
- 37 severe
- 137 moderate
- 3 minor
Most severe, free to view
- KetoconazoleH02CA03severe
- ClarithromycinJ01FA09severe
- KetoconazoleJ02AB02severe
- Darunavir and cobicistatJ05AR14severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Polatuzumab vedotin in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NorwayPolivyOrifarm AS
- SpainPOLIVY 140 MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSIONRoche Registration Gmbh
- FinlandPolivyRoche Registration GmbH
- IrelandPolivy 140 mg powder for concentrate for solution for infusionRoche Registration GmbH
- IcelandPolivyRoche Registration GmbH*
- PolandPolivyRoche Registration GmbH
- BelgiumPolivy 140 mgRoche Registration
- SwedenPolivy 140 mg Pulver till koncentrat till infusionsvätska, lösningRoche Registration GmbH
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Polivy
- Liechtenstein · Polivy
- Norway · Polivy
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/fe616feb-9f15-42e5-84ea-5d4bae1444bd GET /v1/drugs/fe616feb-9f15-42e5-84ea-5d4bae1444bd?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "38221511000001107",
"desc": "Polivy 140mg powder for concentrate for solution for infusion vials (Roche Products Ltd)",
"form": "Powder for solution for infusion",
"vpid": "38235111000001104",
"source": "dmd",
"vtm_id": "788330008",
"strength": "140 mg",
"substance": "Polatuzumab vedotin",
"ingredient": "Polatuzumab vedotin",
"supplier_code": "2085201000001100"
}See everything about polatuzumab vedotin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.